Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6247421 | 0.92 | PTPN5 (0.47) | PTPN1PTPN5KIF11RXRARXRB | |
| SCHEMBL6276650 | 0.92 | KIF11 (0.45) | PTPN1PTPN5MAOAKIF11RXRA | |
| SCHEMBL6247943 | 0.87 | KIF11 (0.48) | KIF11MAOB | |
| SCHEMBL6249067 | 0.87 | KIF11 (0.46) | KIF11 | |
| SCHEMBL6249559 | 0.85 | PTPN1 (0.41) | PTPN1PTPN5MAOAKIF11RXRA | |
| SCHEMBL6265919 | 0.84 | KIF11 (0.39) | PTPN1PTPN5MAOAKIF11RXRA | |
| SCHEMBL147712 | 0.83 | KCNN4 (0.52) | KIF11KCNN4TAAR1 | |
| Hydrochloric Acid SCHEMBL317557 | 0.81 | KCNN4 (0.50) | KIF11KCNN4TAAR1 | |
| Bromide SCHEMBL28680752 | 0.81 | KCNN4 (0.50) | KIF11KCNN4TAAR1 | |
| Iodide SCHEMBL28805520 | 0.81 | KCNN4 (0.50) | KIF11KCNN4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010150-A2 | STABLE EMULSION FORMULATIONS | Amgen Inc. (US) | 2009-01-07 | — | — | EP | claimed |
| WO-2007124465-A2 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-11-01 | — | — | WO | claimed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | claimed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | claimed |
| WO-2010104882-A1 | METHODS OF MODULATING SPERM MOTILITY | AMGEN INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| EP-2114390-A2 | METHODS FOR TREATING PODOCYTE-RELATED DISORDERS | Ruprecht-Karls-Universität Heidelberg (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008075173-A2 | METHODS FOR TREATING PODOCYTE-RELATED DISORDERS | Ruprecht-Karls-Universität Heidelberg (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1509497-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | Amgen Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |